<SEC-DOCUMENT>0001279569-18-000796.txt : 20180424
<SEC-HEADER>0001279569-18-000796.hdr.sgml : 20180424
<ACCEPTANCE-DATETIME>20180424075933
ACCESSION NUMBER:		0001279569-18-000796
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180424
FILED AS OF DATE:		20180424
DATE AS OF CHANGE:		20180424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		18770167

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of April 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">News Release Dated April 24, 2018: ESSA Pharma Enhances R &amp; D Capabilities with Two Key Hires.</A><A HREF="ex991.htm"></A></FONT></P>


</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 24, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED APRIL 24, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA Pharma Enhances R&amp;D Capabilities with Two New
Key Hires</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, April 24, 2018 /CNW/ - ESSA Pharma
Inc. (&quot;ESSA&quot; or the &quot;Company&quot;) (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on the development
of novel small molecule drugs for the treatment of prostate cancer, announced today the appointments of Han-Jie Zhou, Ph.D., Vice
President, Chemistry and Chemistry Manufacturing and Control, and Ronan Le Moigne, Ph.D., Senior Director, Preclinical.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&quot;I am pleased to welcome Drs. Zhou and Le Moigne to ESSA,&quot;
said David R. Parkinson, ESSA Pharma's President and Chief Executive Officer.&nbsp; &quot;We are progressing with multiple pre-clinical
characterization studies in order to select a next-generation clinical candidate to advance our aniten N-terminal domain inhibitor
program and are excited to expand our R&amp;D capabilities with the appointment of these two senior researchers.&nbsp; We look
forward to leveraging their expertise as we advance towards clinical development.&quot;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Dr. Zhou has more than 18 years of experience in oncology
drug discovery and development including medicinal and process chemistry, drug metabolism and pharmacokinetics, chemistry manufacturing
and control, project management, and global outsourcing.&nbsp; Prior to joining ESSA, he was Vice President of Chemistry at Cleave
Biosciences, Group Leader at Proteolix and Scientist at Cytokinetics. Over his career, he contributed to the discovery and development
of KYPROLIS&reg; (carfilzomib), ONX0914 and omecamtiv mecarbil.&nbsp; Dr. Zhou earned his Ph.D. in organic chemistry from the University
of Fribourg, Switzerland, and completed postdoctoral training in the laboratory of Dr. Robert Holton at Florida State University.
He is a named inventor and author on more than 35 patents and publications.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Dr. Le Moigne has more than 12 years of experience in oncology
drug discovery and development, including target validation, clinical candidate selection, pharmacokinetic/ pharmacodynamic relationships,
toxicology, and biomarker development.&nbsp; &nbsp;Prior to joining ESSA, he served as Senior Director of Pharmacology at Cleave
Biosciences, and previously held scientific roles at Sanofi, where Dr. Le Moigne supported the advancement of small molecules and
antibodies in preclinical development.&nbsp; He also supported the clinical development of ZALTRAP&reg; (aflibercept), a VEGF Trap
biologic.&nbsp; Dr. Le Moigne earned his Ph.D. in Pharmacology from the University Paris XI, France.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc.</B><BR>
ESSA is a pre-clinical stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of
castration-resistant prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current
therapies. ESSA believes that its proprietary compounds can significantly expand the interval of time in which patients suffering
from CRPC can benefit from hormone-based therapies, by disrupting the androgen receptor (&quot;AR&quot;) signaling pathway that
drives prostate cancer growth and by preventing AR transcriptional activity by binding selectively to the N-terminal domain (&quot;NTD&quot;)
of the AR. A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated
the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer</B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease, metastatic CPRC (&quot;mCRPC&quot;), and most patients ultimately
succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional
treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including
abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally
experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both
in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking
tumor growth when current therapies are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B><BR>
This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
&quot;potential&quot;, &quot;promising&quot;, &quot;refocus&quot;, statements that an action or event &quot;may&quot;, &quot;might&quot;,
&quot;could&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and includes, but is
not limited to, statements relating to the advancement of ESSA's aniten N-terminal domain inhibitor program and progressing ESSA's
preclinical studies towards clinical development.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market and economic conditions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein, in the Company's second amended and restated prospectus supplement
dated January 5, 2018 and in ESSA's Annual Report on Form 20-F dated December 11, 2017 under the heading &quot;Risk Factors&quot;,
a copy of which is available on ESSA's profile on the SEDAR website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and
as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements
if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian
and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">View original content with multimedia:http://www.prnewswire.com/news-releases/essa-pharma-enhances-rd-capabilities-with-two-new-key-hires-300634873.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/24/c3972.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>David Wood, Chief Financial Officer,
ESSA Pharma Inc., 778-331-0962, dwood@essapharma.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 07:30e 24-APR-18</P>



<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# *T# 2(  A$! Q$!_\0
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H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
